Extended Data Fig. 8: 76E1 is synergistic with RBD antibodies to neutralize SARS-CoV-2 pseudovirus.
From: Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
a, RBD antibodies CB6, P2C1F11 and 28-8 L facilitated 76E1 binding to the cell surface-expressed S proteins of SARS-CoV-2, as determined by flow cytometry, showing as Mean fluorescence intensity (MFI) values. The data are shown as the mean value of duplicates. b-j, The synergistic effect of 76E1 and RBD antibody in neutralizing SARS-CoV-2 pseudovirus. b, e, h, Neutralizing curves of 76E1 and RBD antibodies CB6 (b), P2C1F11 (e) and 28-8 L (h) alone and in combination at a constant ratio with serial 3-fold-diluted concentration from 81 times IC50. A dose of 1 represents the concentration at IC50. The constant ratio indicates the ratio between 76E1 and RBD antibody at IC50. Results are depicted as the mean ± s.d. from three replicates. c, f, i, CI (combination index) values of CB6 (c), P2C1F11 (f) and 28-8 L (i) at ED50 and ED75 (50% and 75% effective dose). The CI values was calculated using the CompuSyn program. The dotted line in red represents CI = 1 below of which was defined as synergism versus top of which as antagonism. d, g, j Summary of the synergistic effect parameters of 76E1 and CB6 (d), P2C1F11 (g) and 28-8 L (j). Dose reduction index (DRI) was calculated by comparing the dose required to reach 50% or 75% virus neutralization when 76E1 or RBD antibody was used alone and in combination. α, Concentrations of 76E1 and RBD antibody in the mixture, respectively. β, DRI of 76E1 and RBD antibody in the mixture, respectively. For all data, representative data are shown from two independent experiments.
